VYNE TherapeuticsVYNE
About: VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
Employees: 13
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
64% more capital invested
Capital invested by funds: $14.3M [Q3] → $23.4M (+$9.12M) [Q4]
50% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 6
6% more funds holding
Funds holding: 32 [Q3] → 34 (+2) [Q4]
1.93% less ownership
Funds ownership: 49.82% [Q3] → 47.89% (-1.93%) [Q4]
100% less funds holding in top 10
Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Joseph Pantginis 20% 1-year accuracy 82 / 415 met price target | 219%upside $4.50 | Buy Maintained | 25 Apr 2025 |
Financial journalist opinion









